Modus Therapeutics Holding AB

MODTX · ST · Healthcare / Biotechnology

0.1725SEK+0.00 (+2.99%)

Price History

Full chart

Market Stats

Previous Close0.1675

Open0.1525

Day Range0.1525 – 0.174

52-Week Range0.208 – 0.596

Volume456.69K

Market Cap66.60M

P/E (TTM)0.00

Forward P/E0.00

EPS-0.26

Dividend Yield0.00%

Beta0.40

50-Day Avg0.3984

200-Day Avg0.3697

About

Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.

Company Details

SectorHealthcare
IndustryBiotechnology
CEODr. John Öhd M.D., Ph.D.
Employees2
HeadquartersOlof Palmes gata 29 IV, Stockholm, Sweden, 111 22, Sweden
Websitehttps://www.modustx.com

Leadership

Dr. John Öhd M.D., Ph.D.Chief Executive Officer · b. 1971
Mr. Claes LindbladCFO & Head of IR · b. 1967

Financials

Income Statement

Currency: SEK	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	-	0	0	0	0	0	0	0
Operating Income	-49.09M	-43.58M	-6.02M	-20.69M	-18.01M	-16.40M	-15.84M	-18.17M
EBITDA	-49.09M	-43.58M	-6.02M	-20.69M	-18.01M	2.00K	-15.84M	-18.17M
Net Income	-49.65M	-43.58M	-6.02M	-20.69M	-18.32M	-17.90M	-15.54M	-18.54M
R&D	41.65M	36.05M	3.72M	13.54M	10.90M	8.48M	9.07M	10.85M
Interest Expense	0	1.00K	1.00K	1.00K	314.00K	1.50M	0	401.00K

Balance Sheet

Currency: SEK	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	46.95M	2.05M	7.49M	21.19M	11.27M	20.04M	4.88M	12.69M
Total Liabilities	23.05M	4.74M	496.00K	5.46M	13.86M	2.36M	2.75M	3.62M
Total Equity	23.90M	-2.69M	7.00M	15.73M	-2.58M	17.68M	2.14M	9.07M
Cash	45.79M	1.38M	7.34M	20.65M	10.42M	19.06M	4.38M	11.37M
Total Debt	-	2.54M	26.00K	-	11.50M	-	-	-
Net Debt	-45.79M	1.16M	-7.32M	-20.65M	1.08M	-19.06M	-4.38M	-11.37M

Cash Flow

Currency: SEK	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-40.06M	-43.90M	-7.23M	-16.08M	-21.72M	-16.68M	-14.68M	-18.07M
Investing Cash Flow	-54.00K	-16.00K	-50.00K	-50.00K	-	-	-	-
Financing Cash Flow	73.83M	3.50M	13.20M	29.43M	11.50M	25.32M	-	25.07M
Capital Expenditure	54.00K	16.00K	0	0	0	0	0	0
Free Cash Flow	-40.12M	-43.91M	-7.23M	-16.08M	-21.72M	-16.68M	-14.68M	-18.07M
FCF to OCF	100.13%	100.04%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

Earnings

Report Date	Nov 18, 2021	Feb 22, 2022	May 16, 2022	Aug 23, 2022	Nov 22, 2022	Feb 22, 2023	May 9, 2023	Aug 23, 2023	Nov 8, 2023	Feb 21, 2024	May 14, 2024	Aug 23, 2024	Nov 20, 2024	Feb 20, 2025	May 14, 2025	Jun 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026
EPS Estimate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS Actual	-0.30	-0.76	-0.19	-0.19	-0.18	-0.58	-0.38	-0.29	-0.19	-0.18	-0.09	-0.13	-0.08	-0.13	-0.08	-0.07	-0.08	-0.04	-0.03	-0.03
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	After-hours	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	-	-	-	-	-

Key Statistics & Ratios

Market Cap66.60M

Enterprise Value53.64M

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.00

Price / Book6.46

EPS-0.26

Book Value0.069

Revenue (TTM)0

Gross Profit (TTM)0

Profit Margin0.00%

Operating Margin0.00%

Return on Equity-743.89%

Return on Assets-167.51%

Shares Outstanding169.04M

Shares Float33.44M

Beta0.40

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Stock Splits

Aug 7, 2025104:41